Advaxis, Inc.

497 articles with Advaxis, Inc.

• Advaxis Announced Listing Transfer to Nasdaq Capital Market and Additional 180-day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

  12/22/2020

  Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it received a positive determination from the Nasdaq Stock Market granting approval of the Company’s request to transfer its listing to the Nasdaq Capital Market from the Nasdaq Global Select Market. The Company’s securities will begin trading on the Nasdaq Capital Market effectiv

• Advaxis, Inc. Announces Closing of $9.2 Million Public Offering

  11/27/2020

  PRINCETON, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the closing of an underwritten public offering of 26,666,666 shares of common stock and warrants to purchase up to 13,333,333 shares of common stock, along with an additional 3,999,999 shares of common stock and 1,999,999 warrants pursuant to the full exercise of the

• Advaxis, Inc. Announces Pricing of $8 Million Public Offering

  11/24/2020

  Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offering of (i) 26,666,666 shares of common stock and warrants to purchase up to 13,333,333 shares of common stock.

• Advaxis, Inc. Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock

  11/23/2020

  Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. In connection with the offering,

• Advaxis Presents Updated Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

  11/9/2020

  Disease control rate of 67% and overall response rate of 17% in first six evaluable patientswith immediate prior progression on KEYTRUDA®

• Advaxis’ ADXS-503 (HOT Lung) Demonstrates Pronounced and Sustained Tumor Control in Ongoing Phase 1/2 Lung Cancer Trial

  10/26/2020

  Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced updated clinical results from the combination arm of the Company’s ongoing Phase 1/2 study evaluating ADXS-503 in combination with KEYTRUDA® (pembrolizumab),

• Advaxis to Present Data from Ongoing ADXS-503 Phase 1/2 Clinical Trial at SITC 2020

  10/15/2020

  Advaxis , Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it will present an ePoster at the 35 th Annual Meeting of the Society for Immunology of Cancer (SITC 2020) to be held virtually November 9-14, 2020. Title: “Phase 1/2 Study of an Off-the-Shelf, Multi-Neoantigen Vector (ADXS-503) Alone and in Combination with Pembrolizumab in Sub

• Advaxis Announces FDA Clearance of New IND for ADXS-504 for Treatment of Prostate Cancer

  9/24/2020

  Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the U.S. Food and Drug Administration (FDA) has cleared a new Investigational New Drug (IND) application for the initiation of an Investigator Sponsored Phase 1 clinical study of ADXS-504,

• Advaxis Reports Third Quarter Ended July 31, 2020 Financial Results and Provides a Business Update

  9/10/2020

  Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced an update on its clinical pipeline and financial results for the third quarter ended July 31, 2020

• Advaxis Announces Resignation of Chief Financial Officer

  9/4/2020

  Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced that Molly Henderson, Executive Vice President and Chief Financial Officer, has resigned effective September 25, 2020 to pursue another business opportunity. Kenneth A. Berlin, Advaxis’ President and Chief Executive Officer, will serve as interim Chief Financial Officer until a new Chi

• Advaxis to Present Corporate Overview at the LD Micro 500 Virtual Conference

  8/27/2020

  Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will present a corporate overview at the LD Micro 500 Virtual Conference, being held virtually September 1 – 4, 2020.

• Advaxis Announces Common Stock Purchase Agreement for up to $20 Million with Lincoln Park Capital

  8/3/2020

  Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced that it has entered into a common stock purchase agreement for up to $20 million with Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor. Upon execution of the purchase agreement, Lincoln Park made an initial purchase of $2 million of common stock at $0.57 per

• Advaxis to be Featured in “Grand Rounds: a Webinar in Biotech and Specialty Pharma,” Hosted by Alliance Global Partners

  6/23/2020

  Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will be featured in a webinar, “Grand Rounds: A Webinar in Biotech and Specialty Pharma,” hosted by James Molloy, Managing Director of Equity Research, Biotechnology and Specialty Pharmaceuticals at Alliance Gl

• Advaxis to Host Second Quarter Financial Results and Business Update Conference Call on Thursday, June 11, 2020

  6/1/2020

  Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, announced today that it will release financial results for the second quarter ended April 30, 2020 before the market opens on Thursday, June 11, 2020. The company will host a conference call at 11:00am EDT on the same day to provide a business update. Thursday, June 11, 11:00 am EDT Webcast: h

• 

  Clinical Catch-Up: May 11-15

  5/18/2020

  Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.

• Advaxis Announces Updated Positive Clinical and Biomarker Data from Ongoing Phase 1/2 ADXS-503 Trial in NSCLC

  5/14/2020

  Sustained clinical benefit seen in patients treated with ADXS-503 in combination with KEYTRUDA® after 16 weeks, including a partial response and stable disease in patients who had most recently progressed on KEYTRUDA® Positive preliminary immunogenicity data with CD8+ T cells generated in all of the first seven patients evaluated for ADXS-503 antigens PRINCETON, N.J., May 14, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the de

• Advaxis Reports First Quarter Ended January 31, 2020 Financial Results and Provides a Pipeline Update

  3/13/2020

  Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced an update on its clinical pipeline and financial results for the first quarter ended January 31, 2020.

• Advaxis to Present at the 2020 LD Micro Virtual Conference

  3/3/2020

  Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis will present at the third annual LD Micro Virtual Conference on March 4, 2020.

• 

  Clinical Catch-Up: February 24-28

  3/2/2020

  The month of February ended with a flurry of clinical trial announcements. Here’s a look.

• Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference

  2/27/2020

  Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced updated results from the combination arms of the Company’s ongoing Phase 1/2 study.